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The very late antigen (VLA)-4 and VLA-5 integrins
mediate hematopoietic progenitor cell attachment to
bone marrow (BM) stroma. Transforming growth fac-
tor-b1 (TGF-b1) is a cytokine present in the BM micro-
environment that has been shown to regulate the syn-
thesis of adhesion elements in several cell types. We
have investigated whether TGF-b1 action on human BM
stromal cells affected the adhesion of progenitor cells
involving integrins VLA-4 and VLA-5. Two precursor cell
lines, pre-B Nalm-6 and the multipotential UT-7, at-
tached to untreated primary stroma and to the human
BM stromal cell line Str-5 preferentially using VLA-4.
However, treatment of the stroma with TGF-b1 resulted
in a significant reduction in the participation of VLA-4
in mediating precursor cell adhesion to stroma and a
concomitant increase in the utilization of VLA-5. This
effect was not exclusive of normal BM stroma. Treat-
ment with TGF-b1 of stroma from multiple myeloma BM
samples produced a substantial increase in VLA-5 use by
the myeloma cell line NCI-H929 to adhere to this stroma.
The differential use of VLA-4 and VLA-5 correlated with
an increase in fibronectin surface expression by stromal
cells in response to TGF-b1. Adhesion assays to purified
fibronectin using Nalm-6 cells showed a predominant
utilization of VLA-4 at low concentrations of this ligand,
whereas higher concentrations resulted in a preferen-
tial use of VLA-5. These results indicate that regulation
of fibronectin expression on BM stromal cells by TGF-b1
results in a modulation of the pattern of integrins used
by the precursor and myeloma cells to adhere to BM
stroma, which could have important consequences on
the proliferation and differentiation of hematopoietic
precursor cells as well as on the localization and growth
of myeloma cells.
The bone marrow stromal cells (BMSC)1 constitute a popu-
lation of different cell types that provide the bone marrow (BM)
microenvironment with a wealth of cytokines necessary for
sustained hematopoiesis and that express membrane ligands
for adhesion receptors on hematopoietic progenitor cells (1).
The integrins VLA-4 and VLA-5 are among the main adhesion
receptors used by CD34high, precursor, and leukemic cells to
attach to stroma, interacting with different regions on fibronec-
tin (FN), whereas VLA-4 can additionally bind to VCAM-1,
which is constitutively expressed by BMSC (2–5).
TGF-b is a multifunctional cytokine present in the BM mi-
croenvironment that is mainly produced by megakaryocytes
and by BMSC (6, 7) and that regulates stem cell proliferation
and B lymphopoiesis (8–10). The levels of TGF-b have been
found to be higher in several leukemias, such as multiple
myeloma and B cell chronic lymphocytic leukemia, compared
with normal bone marrow (11, 12). We have recently charac-
terized the TGF-b1 receptor system on primary human BMSC,
showing the expression of the serine/threonine kinase trans-
ducing type I and II receptors as well as endoglin (13). Little is
known about the effects of TGF-b on stromal cell function.
Potential targets for its action include the control of cell prolif-
eration and the regulation of the synthesis of adhesion ele-
ments, such as extracellular matrix proteins, and extracellular
matrix protein-degrading proteases (14). Changes in the ex-
pression of adhesion elements on BMSC at different niches or
during different stages of differentiation could result in varia-
tions in the adhesion of maturing precursor cells and could also
influence the localization of tumor cells in the BM. In this work,
we have studied the involvement of integrins VLA-4 and VLA-5
in progenitor cell adhesion to TGF-b1-treated stroma.
MATERIALS AND METHODS
Stromal Cell Cultures—Normal BM was obtained after informed
consent from donors for allogeneic bone marrow transplants. Multiple
myeloma BM samples were obtained from untreated patients with
active disease. The stromal cultures were generated as described pre-
viously (13) and maintained in Iscove’s modified Dulbecco’s medium
(IMDM) supplemented with 10% fetal calf serum (complete medium)
and 1025 M hydrocortisone sodium succinate. Non-adherent cells were
removed after 1 week, and upon confluency, the stromal cells were
passaged by trypsin/EDTA. After four passages, they were seeded 1
week before use in 96-well plates for adhesion and cell ELISAs. Our BM
stromal monolayers consisted mainly of fibroblasts and macrophages,
with a low percentage of endothelial cells (13). The human bone marrow
stromal cell line Str-5 was maintained in complete medium (13). For
TGF-b1 treatments, stromal cultures were first incubated in IMDM
supplemented with 1% fetal calf serum and serum replacement medium
(23 TCM, ICN Biomedicals) for 24 h, followed by a 24-h incubation in
the same medium in the presence of recombinant human TGF-b1 (R&D
Systems, Abingdon, United Kingdom), and this medium was removed
by aspiration before assays.
Cells and Antibodies—The pre-B Nalm-6, myeloma NCI-H929, and
Burkitt lymphoma Ramos cell lines were cultured in RPMI 1640 me-
dium supplemented with 10% fetal calf serum (and 50 mM 2-mercapto-
ethanol for the NCI-H929 cells). The multipotential cell line UT-7 (15),
which expresses CD34 and CD33, was grown in a-minimum Eagle’s
medium in the presence of 10% fetal calf serum and 2 ng/ml granulo-
cyte-macrophage colony-stimulating factor. Antibodies used in this
study included monoclonal P3X63 (16), anti-a4 HP1/2 (17), anti-a5
SAM-1 (18), and P1D6 (Life Technologies, Inc.), Bear-1 anti-CD11b (18),
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anti-VCAM-1 4B9 (19), and polyclonal anti-FN central cell-binding
domain Rb110 and anti-FN carboxyl-terminal CS-1-containing cell-
binding domain Rb113.
Measurement of Bioactive TGF-b—TGF-b levels from stromal super-
natants were determined in a bioassay by analyzing the growth inhi-
bition of mink lung epithelial Mv1Lu cells (American Type Culture
Collection CCL 64). Mv1Lu cells were subcultured in IMDM supple-
mented with 10% fetal calf serum in 24-well tissue culture plates at 3 3
104 cells/well. TGF-b1 (0.1–10 ng/ml) or 24-h stromal supernatants in
IMDM supplemented with 1% fetal calf serum and 23 TCM were added
without previous acidification to Mv1Lu cells in triplicates, which were
incubated for 24 h at 37 °C, the last 4 h in the presence of 1 mCi/well
[3H]thymidine (Amersham International, Buckinghamshire, UK). At
the end of incubation, cells were washed with phosphate-buffered saline
and extracted with 0.2 N NaOH, and extracts were neutralized with 1 M
HCl before adding scintillation liquid and analyzed in a b-counter.
Adhesion Assays—Cell lines were labeled in their respective growth
medium with the fluorescent dye BCECF-AM (Molecular Probes, Lei-
den, The Netherlands) and finally resuspended in RPMI 1640 medium
containing 0.4% bovine serum albumin (adhesion medium). For cell
adhesion to purified plasma fibronectin (Sigma), increasing concentra-
tions of this ligand were coated overnight at 4 °C in 100 mM NaHCO3
(pH 8.8), followed by 2-h incubation at 37 °C and then blocking with
0.4% bovine serum albumin in the same solution for 2 h at 37 °C.
Preincubations with antibodies were carried out at 37 °C for 15 min,
and the antibodies were removed before adhesion. To untreated or
TGF-b1-treated stroma or fibronectin in 96-well dishes (Falcon) was
added 50 ml of adhesion medium 20 min before adhesion, and after
removing it, labeled cells (5 3 104 cells/well) were incubated with the
stroma or with fibronectin for 20 min at 37 °C. Unbound cells were
removed by three washes with RPMI 1640 medium, and adherent cells
were quantified using a fluorescence analyzer (CytoFluor 2300, Milli-
pore Corp.).
Cellular ELISA—Untreated or TGF-b1-treated stromal monolayers
were fixed with 3.7% formaldehyde in phosphate-buffered saline,
washed three times with Tris-buffered saline, and blocked with 3%
bovine serum albumin in Tris-buffered saline. After removing the block-
ing solution, cells were incubated for 1 h at 22 °C with the primary
antibodies, washed with Tris-buffered saline in the presence of 0.05%
Tween 20, and further incubated for 1 h at 22 °C with peroxidase-
conjugated goat anti-rabbit Ig (Dako, Glostrup, Denmark). Monolayers
were finally washed and incubated with ABTS (Boehringer Mannheim)
in the dark before measuring in an ELISA reader (Multiskan Bichro-
matic, Labsystems, Helsinki, Finland) at 405 nm.
Flow Cytometry—Preparation of the stromal cells for flow cytometry
analysis was performed as described previously (13). Approximately 105
stromal cells were incubated with saturating concentrations of primary
antibodies at 4 °C for 45 min. After washing, fluorescein isothiocyanate-
conjugated rabbit anti-mouse Ig (Dako) was added and further incu-
bated at 4 °C for 30 min. Samples were analyzed using a Coulter Epics
XL flow cytometer.
RESULTS
To investigate whether TGF-b1 action on BMSC could influ-
ence hematopoietic precursor and myeloma cell adhesion me-
diated by integrins VLA-4 and VLA-5, we first measured the
levels of bioactive TGF-b present in primary human BMSC
(HBM-Str) cultures, in the stromal cell line Str-5, and in mul-
tiple myeloma BMSC (MM-Str) cultures. Bioassays for TGF-b
activity using the TGF-b responder cell line Mv1Lu showed
TGF-b-dependent activity corresponding to 0.3–0.6 ng/ml in
HBM-Str cells cultured for 24 h, whereas Str-5 and MM-Str
cells secreted bioactive TGF-b in the range of 2–2.5 ng/ml
(Fig. 1).
Incubation of primary stroma with 1 ng/ml TGF-b1 resulted
in a decrease in the adhesion of the pre-B cell line Nalm-6
compared with the adhesion to untreated stroma (Fig. 2A). The
anti-a4 HP1/2 mAb significantly inhibited (30–40%; p , 0.05)
the adhesion of Nalm-6 cells to untreated stroma, but inhibi-
tion by HP1/2 was consistently decreased when the adhesion
was performed on TGF-b1-incubated stroma. In contrast, the
anti-a5 SAM-1 mAb minimally inhibited Nalm-6 cell adhesion
to untreated stroma; however, incubation of stroma with
TGF-b1 resulted in a blockade of cell adhesion by SAM-1, as
well as by another anti-a5 mAb called P1D6 (data not shown),
of ;50% (p , 0.05) (Fig. 2A). The results of inhibition of Nalm-6
cell adhesion using a mixture of anti-a4 and anti-a5 mAbs
mimicked those of inhibition with single mAbs. Thus, HP1/2
and SAM-1 together inhibited slightly better than HP1/2 alone
the adhesion of Nalm-6 cells to untreated stroma (Fig. 2A),
reflecting a major VLA-4 use. After incubation of the stroma
with TGF-b1, the combination of both antibodies inhibited
similarly to SAM-1 alone, indicating a predominant VLA-5
utilization. The anti-VCAM-1 4B9 mAb inhibited by 15–20%
the adhesion of Nalm-6 cells to either untreated or TGF-b1-
treated stroma (Fig. 2A). The effect of TGF-b1 action on Nalm-6
cell adhesion to HBM-Str was also evident when we preincu-
bated the Str-5 cells with increasing concentrations of TGF-b1,
although in this case, higher concentrations of the cytokine
were needed to obtain a substantial blocking of Nalm-6 cell
adhesion by the anti-a5 mAb (Fig. 2B). In parallel experiments,
the SAM-1 and P1D6 mAbs did not inhibit the adhesion of the
VLA-5-negative B cell line Ramos either to untreated or TGF-
b1-treated HBM-Str cells (data not shown).
As for the case of Nalm-6 cells, preincubation of HBM-Str
cells with TGF-b1 resulted in a decrease in the adhesion of the
multipotential cell line UT-7 (Fig. 2C). Interestingly, both
HP1/2 and, to a lesser extent, SAM-1 inhibited the adhesion of
UT-7 cells to untreated stroma. However, TGF-b1 treatment of
the stroma resulted in a notable reduction in HP1/2 inhibition
of cell adhesion, whereas inhibition by SAM-1 remained un-
changed, indicating a predominant VLA-5 use. We could not
observe any clear effect of the anti-VCAM-1 mAb on UT-7 cell
adhesion to stroma, suggesting that VLA-4 on these cells
mainly interacts with fibronectin.
To study if the differential use of VLA-4 and VLA-5 could
also be observed using leukemic BM stroma, we generated
stromal cell cultures from multiple myeloma BM samples and
analyzed the effect of their incubation with TGF-b1 on the
adhesion of the myeloma-derived cell line NCI-H929. These
monolayers expressed abundant fibronectin and substantial
levels of VCAM-1 (data not shown).2 Similarly to Nalm-6 and
UT-7 cells, NCI-H929 cells adhered significantly less to TGF-
b1-treated compared with untreated multiple myeloma stroma
(Fig. 3). The anti-a4 HP1/2 mAb inhibited NCI-H929 cell ad-
hesion to untreated stroma by ;40% (p , 0.05) and to a lower
2 M. M. Robledo, F. Sanz-Rodriguez, A. Hidalgo, and J. Teixido´,
manuscript in preparation.
FIG. 1. Secretion of bioactive TGF-b by BMSC. Stromal cultures
from healthy donors (n 5 4; HBM-Str), the stromal cell line Str-5 (n 5
4), and multiple myeloma BM samples (n 5 4; MM-Str) were incubated
for 24 h in IMDM, 1% fetal calf serum, and 23 TCM, and the superna-
tants were analyzed for their TGF-b content in a bioassay using Mv1Lu
cells. Data represent the mean 6 S.D. of triplicate samples from a
representative experiment.
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extent after treatment with TGF-b1. As observed for Nalm-6
cells, a low degree of inhibition of NCI-H929 cell adhesion to
untreated stroma was detected with the anti-a5 mAb P1D6,
but after TGF-b1 incubation of the multiple myeloma stroma, a
high induction of blocking by this antibody was obtained (Fig.
3). The anti-VCAM-1 4B9 mAb inhibited normally 15–25% of
NCI-H929 cell adhesion to both untreated and TGF-b1-treated
multiple myeloma stroma.
One of the targets of TGF-b action is the control of extracel-
lular matrix protein synthesis (14, 20). As fibronectin is ex-
pressed by stromal cells and is a ligand for both VLA-4 and
VLA-5, we analyzed whether FN levels on the surface of stro-
mal cells were affected by TGF-b1. Cellular ELISAs consist-
ently showed an augmentation in FN deposition by HBM-Str
cells in response to TGF-b1, as measured by antibodies against
the FN central cell-binding domain and the CS-1-containing
region (Fig. 4). These results were confirmed by [35S]Met/Cys
metabolic labeling of stroma, where a 2.5-fold increase in gel-
atin-bound extracellular FN was observed upon TGF-b1 treat-
ment (Fig. 4). When the expression of VCAM-1 on stromal cells
was analyzed by flow cytometry, a significant reduction was
obtained in response to TGF-b1 (data not shown), similar to
previous results (21). The same experiments showed no effect of
TGF-b1 on VLA-b1 or CD11b expression on these cells.
To investigate possible mechanisms underlying the potential
preferential receptor usage, we carried out cell adhesion assays
with increasing concentrations of human plasma fibronectin
using Nalm-6 cells. The cells adhered to fibronectin in a con-
centration-dependent manner in the presence of control P3
antibodies, reaching saturation at ;30 mg/ml (Fig. 5). The
inhibition of Nalm-6 cell adhesion to fibronectin by anti-a4 and
anti-a5 antibodies displayed three different patterns, depend-
ing on the concentrations of fibronectin used. At the lowest
concentrations of FN (2–4 mg/ml), the anti-a4 HP1/2 mAb
notably inhibited Nalm-6 cell adhesion, whereas the anti-a5
P1D6 mAb did not block, suggesting a predominant VLA-4 use
(Fig. 5). When the concentration of FN was increased (8–12
mg/ml), HP1/2 showed no or modest inhibition of Nalm-6 cell
adhesion, whereas P1D6 significantly inhibited this adhesion,
indicating a preferential VLA-5 utilization. At the highest con-
centrations of fibronectin (.16 mg/ml), both P1D6 and HP1/2
inhibited Nalm-6 cell adhesion, although the former inhibited
always to a higher extent (Fig. 5). In the same experiments, a
mixture of antibodies against the FN central cell-binding do-
FIG. 2. Effect of TGF-b1 treatment of human BMSC on VLA-4-
and VLA-5-dependent Nalm-6 and UT-7 cell adhesion. HBM-Str
(A (n 5 4) and C (n 5 3)) and Str-5 (B (n 5 4)) monolayers were
incubated for 24 h in the absence or presence of the indicated concen-
trations of TGF-b1, which was removed before adhesion. BCECF-AM-
labeled Nalm-6 and UT-7 cells were preincubated for 15 min at 37 °C
with optimal concentrations of anti-a4 HP1/2, anti-a5 SAM-1, anti-
VCAM-1 4B9, or control P3 mAb before the adhesion assay. Adhesion
was quantified in a fluorescence analyzer. **, adhesion was signifi-
cantly inhibited (p , 0.05) according to Student’s two-tailed t test; *,
inhibition was observed, but was not quite low enough to meet the p ,
0.05 confidence level.
FIG. 3. Effect of TGF-b1 treatment of multiple myeloma stroma
on VLA-4- and VLA-5-dependent myeloma NCI-H929 cell adhe-
sion. Multiple myeloma stromal cells were incubated for 24 h in the
absence or presence of TGF-b1, and the adhesion of NCI-H929 cells (n 5
3), previously incubated with the indicated mAb, was quantified with a
fluorescence analyzer. **, adhesion was significantly inhibited (p ,
0.05) according to Student’s two-tailed t test; *, inhibition was observed,
but was not quite low enough to meet the p , 0.05 confidence level.
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main and the CS-1-containing region fully inhibited Nalm-6
cell adhesion when they were preincubated with the fibronec-
tin-coated wells (data not shown), demonstrating the specificity
of the adhesion.
DISCUSSION
This study describes novel modulatory roles for TGF-b1 in
the adhesion of hematopoietic precursor and myeloma cells to
BM stroma. The important finding is that TGF-b1 action on
human BMSC resulted in a significant reduction in the partic-
ipation of VLA-4 in mediating precursor and myeloma cell
adhesion to the stroma, linked to an increase in VLA-5 involve-
ment in such adhesion. As shown in Table I, the ratio of VLA-5
versus VLA-4 utilization by Nalm-6 and UT-7 cells increased
10-fold after treatment of the stroma with TGF-b1, whereas
this ratio was close to 5-fold in the case of NCI-H929 cells, as
determined from values of inhibition of cell adhesion. The re-
sults were obtained using TGF-b1 concentrations similar to
those found in the supernatants from normal and multiple
myeloma stromata, although in UT-7 cells, slightly higher
amounts of TGF-b1 were required. We detected lower levels of
TGF-b in multiple myeloma stromal cultures compared with a
previous report (11), which could be due to the different meth-
ods of measurement, as we analyzed bioactive TGF-b, whereas
the other study used an ELISA. The differential effects on
VLA-4- and VLA-5-mediated cell adhesion are likely at the
attachment and possibly spreading levels, as we performed
short adhesion assays (20 min), and thus, little, if any, cell
migration took place in our system. In addition, it has been
reported that most of VLA-4-mediated B cell precursor adhe-
sion to stroma occurs in the first 15 min of cell attachment (22),
and therefore, our results were obtained under conditions fa-
voring VLA-4 activity. The modulation of VLA-4 and VLA-5 use
by TGF-b1 treatment of stroma takes place in the absence of
any exogenously added TGF-b1 in the precursor cell lines, and
thus, it is independent of a possible increase in VLA-5 expres-
sion due to this cytokine, as has been reported for several cell
types (23, 24).
Associated with the decreased implication of VLA-4 in me-
diating precursor and myeloma cell adhesion to TGF-b1-
treated stroma, there was a reduction in adhesion to stroma.
A diminished B cell precursor cell adhesion to stroma prein-
cubated with TGF-b1 was also previously reported, which
was linked to a reduced expression of VCAM-1 (21). In the
present work, we observed a moderate participation of the
VLA-4/VCAM-1 adhesion pathway in Nalm-6 and NCI-H929
cells, as detected by antibody inhibition of the adhesion, but
this interaction was not reduced upon stroma treatment with
TGF-b1, suggesting that other adhesion pathways might be
affected. This suggests that most of the VLA-4-dependent
precursor and myeloma cell adhesion to untreated stroma
that we observed takes place by attachment to fibronectin.
The data also indicate that the increase in VLA-5 involve-
ment in cell adhesion to TGF-b1-treated stroma does not
restore the reduced adhesion.
The binding of TGF-b1 to the stroma resulted in an increase
in the levels of fibronectin expressed on the surface of stromal
cells. Although both the CS-1 and central cell-binding domains
of FN were augmented by TGF-b1, the precursor and myeloma
cells used predominantly VLA-5 to interact with FN on TGF-
b1-treated stroma. To gain some insight into the mechanisms
leading to the preferential use of VLA-5 after increased fi-
bronectin deposition on BMSC by TGF-b1, we tested whether
changes in the concentration of purified fibronectin could in-
fluence the integrins utilized to mediate cell adhesion. The
results obtained in the lower and likely more physiological
FIG. 4. Effect of TGF-b1 treatment of human BMSC on fi-
bronectin expression. HBM-Str cells were incubated for 24 h with 2
ng/ml TGF-b1, and the expression of the central cell-binding domain
(CBD-RGD) and the carboxyl-terminal CS-1 region of FN was analyzed
by cellular ELISA using polyclonal antibodies Rb110 and Rb113, re-
spectively. Inset, stromal cells that had been incubated for 24 h in the
absence (2) or presence (1) of TGF-b1 were metabolically labeled for
3 h with [35S]Met/Cys (Amersham Pharmacia Biotech) maintaining the
cytokine, and extracellular matrix proteins were extracted in a urea-
containing buffer as described (20). Extracts were incubated overnight
at 4 °C either with Sepharose CL-4B (lane a) or with gelatin-Sepharose
CL-4B (lanes b and c). Complexes were washed, and FN was released by
resuspending the beads in electrophoresis sample buffer and heating at
100 °C for 2 min. Electrophoresis was carried out using 5% polyacryl-
amide gels, and bands were visualized with a PhosphorImager.
FIG. 5. Effect of anti-a4 and anti-a5 antibodies on adhesion of
Nalm-6 cells to fibronectin. BCECF-AM-labeled Nalm-6 cells were
incubated with saturating concentrations of anti-a4 HP1/2, anti-a5
P1D6, or control P3 mAb, and after removing the antibodies by centrif-
ugation, cells were added to wells coated with increasing concentrations
of fibronectin and incubated for 20 min at 37 °C. Adhesion was quan-
tified in a fluorescence analyzer. Data represent the mean 6 S.D. of
triplicate samples from a representative result of five separate
experiments.
TABLE I
Effect of treatment of BM stroma with TGF-b1 on the differential use
of VLA-4 and VLA-5 by Nalm-6, UT-7, and NCI-H929 cells
Shown are the ratios corresponding to values of inhibition of cell
adhesion obtained with anti-a5 and anti-a4 mAbs from the experiments
shown in Figs. 2 and 3.
Cell line
a5/a4 ratio inhibition 2/1TGF-b1
ratio2TGF-b1 1TGF-b1
Nalm-6 0.14 1.40 10
UT-7 0.52 5.25 10
NCI-H929 0.46 2.16 4.7
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range of FN concentrations mimicked those from adhesion to
TGF-b1-treated stroma. Thus, VLA-4 was the predominant
receptor used at the lowest concentrations of FN inside this
range, whereas VLA-5 was the preferential integrin utilized
when the concentration of FN was increased. At high concen-
trations of fibronectin, VLA-5 use was still higher than VLA-4
use, although the latter retained considerable participation in
adhesion to fibronectin. These results suggest that the concen-
trations of fibronectin modulate the receptor used to mediate
cell adhesion, and therefore, TGF-b1 regulation of the expres-
sion levels of fibronectin on BMSC finely tunes the pattern of
the integrins that will be used by the precursor and myeloma
cells to interact with the stroma.
The a4 integrins are required for normal development of
both B and T precursor cells in bone marrow (25), and long-
term BM cultures have demonstrated the involvement of
VLA-4 in lymphopoiesis (26), evidencing the importance of
VLA-4-mediated adhesion during hematopoiesis. It is well es-
tablished that VLA-4 and VLA-5 on stem and precursor cells as
well as on several leukemic cells mediate attachment to their
ligands on BMSC (2–5). This interaction is important for the
differentiation and proliferation of hematopoietic progenitor
cells. For instance, VLA-4/FN interaction is required for termi-
nal maturation of Ig-secreting BM cells (27). In addition,
VLA-4- and VLA-5-mediated cell adhesion to FN decreases the
proliferation of both normal hematopoietic and chronic myelog-
enous leukemia progenitors (28, 29), and it has been reported
that VLA-5/FN interaction induces apoptosis of hematopoietic
progenitor cells (30). TGF-b is present in the BM microenvi-
ronment, and it is conceivable that changing amounts of this
cytokine in different niches of BM could influence the regula-
tion of hematopoiesis. BMSC secrete TGF-b1 and have the
TGF-b1 receptor system necessary for signaling by this cyto-
kine (13). The differential use of VLA-4 and VLA-5 by progen-
itor and myeloma cells to adhere to stroma after binding of
TGF-b1 to their receptors on the stromal cells suggests a mech-
anism by which changing adhesive interactions might lead to a
modulation of hematopoietic progenitor cell proliferation and
differentiation. Additionally, the differential contribution of
VLA-4 and VLA-5 to the mediation of myeloma cell attachment
to multiple myeloma stroma could influence the localization
and proliferation of the malignant plasma cells in bone
marrow.
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